908 Devices (MASS) Competitors

908 Devices (NASDAQ:MASS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Do institutionals and insiders hold more shares of MASS or EYPT?

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 23.7% of 908 Devices shares are owned by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has preferable earnings and valuation, MASS or EYPT?

908 Devices has higher revenue and earnings than Eyepoint Pharmaceuticals. 908 Devices is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$59.63M	3.88	-$72.21M	-$0.54	-11.94
Eyepoint Pharmaceuticals	$43.27M	18.85	-$130.87M	-$2.68	-4.41

Is MASS or EYPT more profitable?

908 Devices has a net margin of -30.54% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 908 Devices' return on equity of -24.30% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-30.54%	-24.30%	-18.55%
Eyepoint Pharmaceuticals	-337.93%	-63.80%	-50.72%

Does the media favor MASS or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than 908 Devices. MarketBeat recorded 3 mentions for Eyepoint Pharmaceuticals and 1 mentions for 908 Devices. Eyepoint Pharmaceuticals' average media sentiment score of 0.87 beat 908 Devices' score of 0.20 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer MASS or EYPT?

908 Devices currently has a consensus price target of $8.00, suggesting a potential upside of 24.03%. Eyepoint Pharmaceuticals has a consensus price target of $25.38, suggesting a potential upside of 114.50%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Eyepoint Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, MASS or EYPT?

908 Devices has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.

Summary

908 Devices beats Eyepoint Pharmaceuticals on 9 of the 17 factors compared between the two stocks.